ASP Isotopes Announces Proposed Public Offering of Common Stock
ASP Isotopes (NASDAQ: ASPI) has announced the commencement of an underwritten public offering of its common stock shares. The company plans to grant underwriters a 30-day option to purchase up to an additional 15% of the shares sold in the offering. Canaccord Genuity will act as sole bookrunner for the proposed offering. The offering will be conducted through a shelf registration statement on Form S-3, which has been declared effective by the SEC. The final terms will be disclosed in a final prospectus supplement to be filed with the SEC.
ASP Isotopes (NASDAQ: ASPI) ha annunciato l'inizio di un'offerta pubblica sottoscritta delle sue azioni ordinarie. L'azienda prevede di concedere agli underwriter un'opzione di acquisto di ulteriori azioni, pari fino al 15% delle azioni vendute nell'offerta, per un periodo di 30 giorni. Canaccord Genuity agirà come bookrunner esclusivo per l'offerta proposta. L'offerta sarà condotta tramite una dichiarazione di registrazione su Form S-3, che è stata dichiarata efficace dalla SEC. I termini finali saranno divulgati in un supplemento di prospetto finale che sarà depositato presso la SEC.
ASP Isotopes (NASDAQ: ASPI) ha anunciado el inicio de una oferta pública garantizada de sus acciones ordinarias. La empresa planea otorgar a los suscriptores una opción de compra de hasta un 15% adicional de las acciones vendidas en la oferta durante un período de 30 días. Canaccord Genuity actuará como único encargado de libros para la oferta propuesta. La oferta se llevará a cabo mediante una declaración de registro en el Formulario S-3, que ha sido declarada efectiva por la SEC. Los términos finales se revelarán en un suplemento del prospecto final que se presentará ante la SEC.
ASP Isotopes (NASDAQ: ASPI)는 보통주 공개 매각의 시작을 발표했습니다. 이 회사는 인수자에게 매각된 주식의 최대 15%를 구매할 수 있는 30일 옵션을 부여할 계획입니다. Canaccord Genuity는 제안된 공모의 단독 북런너 역할을 할 것입니다. 이 공모는 SEC에 의해 효력이 발생된 S-3 양식으로 등록된 서류를 통해 진행됩니다. 최종 조건은 SEC에 제출될 최종 투자설명서 보충 자료에서 공개될 것입니다.
ASP Isotopes (NASDAQ: ASPI) a annoncé le début d'une offre publique souscrite de ses actions ordinaires. L'entreprise prévoit d'accorder aux souscripteurs une option d'achat de 30 jours pour acquérir jusqu'à 15 % supplémentaires des actions vendues dans le cadre de l'offre. Canaccord Genuity agira en tant que chef de file exclusif de l'offre proposée. L'offre sera réalisée par l'intermédiaire d'un formulaire d'enregistrement S-3, qui a été déclaré effectif par la SEC. Les conditions finales seront divulguées dans un supplément de prospectus final qui sera déposé auprès de la SEC.
ASP Isotopes (NASDAQ: ASPI) hat den Beginn eines unterzeichneten öffentlichen Angebots für seine Stammaktien angekündigt. Das Unternehmen plant, den Underwritern eine 30-tägige Option zu gewähren, um bis zu 15% zusätzliche Aktien, die im Angebot verkauft wurden, zu erwerben. Canaccord Genuity wird als alleiniger Bookrunner für das vorgeschlagene Angebot fungieren. Das Angebot wird durch eine Regulierungsanmeldung auf Formular S-3 durchgeführt, die von der SEC für wirksam erklärt wurde. Die endgültigen Bedingungen werden in einem endgültigen Prospektzusatz angegeben, der bei der SEC eingereicht wird.
- None.
- Potential dilution of existing shareholders through new common stock offering
- Uncertainty regarding the offering size and terms
- Market-dependent completion risk
Insights
This public offering announcement signals a significant capital-raising initiative that could substantially impact ASPI's financial position. With a current market cap of
The inclusion of a 15% overallotment option provides flexibility to meet additional demand and potentially increase the total capital raised. However, the lack of specified pricing and share count creates uncertainty around the offering's ultimate impact. The effective S-3 shelf registration indicates preparedness for this capital raise, though market conditions will heavily influence its success.
WASHINGTON, Oct. 31, 2024 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes” or the “Company”) today announced that it has commenced an underwritten public offering of shares of its common stock. ASP Isotopes intends to grant the underwriters a 30-day option to purchase up to an additional
Canaccord Genuity is acting as sole bookrunner for the proposed offering.
A shelf registration statement on Form S-3 relating to these securities has been filed with the Securities and Exchange Commission (SEC) and has been declared effective by the SEC. The proposed offering is being made only by means of a prospectus and a related prospectus supplement. These documents are or will be available on the SEC’s website at www.sec.gov. Copies of the preliminary prospectus supplement, dated October 31, 2024, and the accompanying prospectus, dated June 12, 2024, relating to the proposed offering may also be obtained by contacting Canaccord Genuity LLC, Attention: Syndication Department, 1 Post Office Square, 30th Floor, Boston, MA 02109, or by email at prospectus@cgf.com. The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About ASP Isotopes Inc.
ASP Isotopes Inc. is a development stage advanced materials company dedicated to the development of technology and processes to produce isotopes for use in multiple industries. The Company employs proprietary technology, the Aerodynamic Separation Process (“ASP technology”). The Company’s initial focus is on producing and commercializing highly enriched isotopes for the healthcare and technology industries. The Company also plans to enrich isotopes for the nuclear energy sector using Quantum Enrichment technology that the Company is developing. The Company has isotope enrichment facilities in Pretoria, South Africa, dedicated to the enrichment of isotopes of elements with a low atomic mass (light isotopes).
Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, those regarding ASP Isotopes’ plans to consummate its proposed public offering and the anticipated final terms, timing and completion of the proposed offering. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “hope,” “may,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “target,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from current expectations and beliefs, including, but not limited to: risks and uncertainties related to whether or not ASP Isotopes will be able to raise capital through the sale of shares of common stock, the final terms of the proposed offering, market and other conditions, the satisfaction of customary closing conditions related to the proposed public offering, the impact of general economic, industry or political conditions in the United States or internationally and other important risk factors set forth under the caption “Risk Factors” in the preliminary prospectus supplement filed with the SEC, in ASP Isotopes’ Annual Report on Form 10-K for the year ended December 31, 2023 and in any other subsequent filings made with the SEC by ASP Isotopes. There can be no assurance that ASP Isotopes will be able to complete the proposed public offering on the anticipated terms, or at all. Any forward-looking statements contained in this press release speak only as of the date hereof, and ASP Isotopes specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.
Contacts
Jason Assad– Investor relations
Email: Jassad@aspisotopes.com
Telephone: 561-709-3043
FAQ
What type of offering did ASP Isotopes (ASPI) announce on October 31, 2024?
Who is the bookrunner for ASP Isotopes (ASPI) October 2024 public offering?